tiprankstipranks
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
PremiumPress ReleasesUPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
5M ago
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
PremiumPress Releases
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
5M ago
Galectin Therapeutics expects cash to fund operations through December 2024
PremiumThe Fly
Galectin Therapeutics expects cash to fund operations through December 2024
5M ago
Galectin Therapeutics nominates Benjamin Carson to board of directors
PremiumThe FlyGalectin Therapeutics nominates Benjamin Carson to board of directors
6M ago
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
PremiumPress Releases
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
6M ago
Galectin Therapeutics reports DSMB concludes NAVIGATE can continue as designed
PremiumThe Fly
Galectin Therapeutics reports DSMB concludes NAVIGATE can continue as designed
7M ago
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
PremiumPress ReleasesGalectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
7M ago
Galectin Therapeutics to present data on liver cirrhosis at NASH meeting
PremiumThe Fly
Galectin Therapeutics to present data on liver cirrhosis at NASH meeting
7M ago
Galectin Therapeutics reports Q2 EPS (15c) vs (16c) last year
PremiumThe Fly
Galectin Therapeutics reports Q2 EPS (15c) vs (16c) last year
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100